Therapeutics Alliances

A unique and comprehensive drug accelerator that identifies select NYU projects to facilitate dealmaking with investors and biopharmaceutical companies.

‹ Home › For Innovators › Funding Programs › Therapeutics Alliances (Innovators)

Launched in 2013, Therapeutics Alliances facilitates the translation of academic biomedical research conducted at NYU into successful industry partnerships focused on developing new therapeutics.

Our success is built on the legacies of blockbuster drugs such as Remicade and Sutent, which were based on licensed NYU Langone research and have helped treat more than 1 million people.

About Therapeutics Alliances

Therapeutics Alliances is a unique and comprehensive drug accelerator that operates like a “virtual biotechnology company” to identify and de-risk select NYU projects and enable greater dealmaking with investors and biopharmaceutical companies.

We provide a variety of resources involving target discovery and validation, assay development, hit finding, and hit-to-lead optimization for small molecules, biologics, and other modalities. In addition to funding, we bring together a dedicated internal staff of project managers and analysts as well as experienced external biopharmaceutical consultants, including medicinal chemists, in vitro pharmacologists, biologics experts, peptide chemists, and more.

Therapeutics Alliances utilizes many world-class contract research organizations that specialize in drug discovery services such as high-throughput screening, virtual screening, biologics, medicinal chemistry, biochemical assays, drug metabolism and pharmacokinetics, and more.

All our projects receive resources customized to meet the specific scientific and business needs required to secure a quality partnership with biopharmaceutical companies and investors. We seamlessly align each project’s scientific work with related business development and intellectual property efforts to maximize the likelihood of completing successful deals.

Request for Proposals

TA is now accepting proposal for the 2026 Translational Awards RFP to fund up to 15 projects advancing innovative preclinical research through early-stage drug target selection, drug target validation, or hit-to-lead compound screening.

This translational award is designed to provide a substantial boost to innovative, intramural preclinical research programs in any therapeutic area or modality. Under the aegis of Therapeutics Alliances, the projects will be directed specifically to advancing target selection, target validation, or initial hit-to-lead screens. The winning projects will be managed by Therapeutics Alliances and have a duration of one calendar year spanning from September 1, 2025 to August 31, 2026.

Proposals are due by February 28, 2025. Learn more about the Request for Proposals and how to apply

Therapeutics Alliances Outcomes

100+

Projects Reviewed

50+

Projects Funded

10+

Startups Spun Out

$15M+

Raised in Complementary External Funding

20+

Active Projects

For Biomedical Researchers

Faculty, postdoctoral fellows, and graduate students who are working on a potentially interesting pathway that may play a key role in human disease are encouraged to discuss such projects with our staff members. We then initiate a review and provide feedback and analysis in a transparent and efficient manner to determine if and what resources can be provided to advance a potential project.

For each candidate opportunity, we specifically assess the evidence, gaps, and cost–benefit related to target validation, feasibility, translatability, commercial and nonprofit interest, and intellectual property.

Contact

If you are an NYU researcher and have a research project that you would like us to consider, or if you have any other related inquiries, please email Gaspar Taroncher-Oldenburg, director of Therapeutics Alliances, at gaspar.taroncher-oldenburg@nyulangone.org.

For investors, companies, and nonprofits interested in providing services or partnering with us, learn more here.